The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man

References

• InagamiTA memorial to Robert Tiegerstedt: the centennial of renin discoveryHypertension19983269539579856956
   PubMed Web of Science ®Google Scholar
• PaulMPoyan MehrAKreutzRPhysiology of local renin-angiotensin systemsPhysiol Rev200686374780316816138
   PubMed Web of Science ®Google Scholar
• de GasparoMCattKJInagamiTWrightJWUngerTInternational union of pharmacology. XXIII. The angiotensin II receptorsPharmacol Rev200052341547210977869
   PubMed Web of Science ®Google Scholar
• NguyenGContrepasAThe (pro)renin receptorsJ Mol Med200886664364618322668
   PubMed Web of Science ®Google Scholar
• IsrailiZHClinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertensionJ Hum Hypertens200014Suppl 1S73S8610854085
   PubMed Web of Science ®Google Scholar
• SongJCWhiteCMPharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonistsPharmacotherapy20002013013910678291
   PubMed Web of Science ®Google Scholar
• PittBPoole-WilsonPASegalRfor the Losartan Heart Failure Survival Study ELITE IIEffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE IILancet200035592151582158710821361
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRfor the Collaborative Study GroupRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDfor the RENAAL Study InvestigatorsEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBrochner-MortensenJfor the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study GroupThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med201;3451287087811565519
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGfor the Valsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSEfor the LIFE Study GroupCardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• VibertiGWheeldonNMfor the Microalbuminuria Reduction with Valsartan (MARVAL) Study InvestigatorsMicroalbuminuria reduction with valsartan in patients with type 2 diabetes mellitusCirculation2002106667267812163426
   PubMed Web of Science ®Google Scholar
• DicksteinKKjekshusJfor the OPTIMAAL Study GroupEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist LosartanLancet2002360933575276012241832
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIfor the SCOPE Study GroupThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAfor the Acute Candesartan Cilexetil Therapy in Stroke Survivors Study GroupThe ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke SurvivorsStroke20033471699170312817109
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKfor the CHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet2003362938677778113678871
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003203491893190614610160
   PubMed Web of Science ®Google Scholar
• LindholmLHPerssonMAlaupovicPCarlbergBSvenssonASamuelssonOMetabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)J Hypertens20032181563157412872052
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMfor the VALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• BarnettAHBainSCBouterPfor the Diabetics Exposed to Telmisartan and Enalapril Study GroupAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med2004351191952196115516696
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiAfor the MOSES Study GroupMorbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES)Stroke20053661218122615879332
   PubMed Web of Science ®Google Scholar
• MochizukiSDahlöfBShimizuMfor the Jikei Heart Study groupValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyLancet200736995711431143917467513
   PubMed Web of Science ®Google Scholar
• ONTARGET InvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLfor the PRoFESS Study GroupTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsYusufSTeoKEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• SjølieAKKleinRPortaMfor the DIRECT Programme Study GroupEffect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trialLancet200837296451394140218823656
   PubMedGoogle Scholar
• MassieBMCarsonPEMcMurrayJJfor the I-PRESERVE InvestigatorsIrbesartan in Patients with Heart Failure and Preserved Ejection FractionN Engl J Med2008359232456246719001508
   PubMed Web of Science ®Google Scholar
• HallerHVibertiGCMimranAPreventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyJ Hypertens200624240340816508590
   PubMed Web of Science ®Google Scholar
• DisertoriMLatiniRMaggioniAPfor the GISSI-AF InvestigatorsRationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrenceJ Cardiovasc Med (Hagerstown)200671293816645357
   PubMed Web of Science ®Google Scholar
• ConnollySYusufSBudajAfor the ACTIVE InvestigatorsRationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular eventsAm Heart J200615161187119316781218
   PubMed Web of Science ®Google Scholar
• KonstamMAPoole-WilsonPADicksteinKDrexlerHJusticeSJKomajdaMDesign of the heart failure endpoint evaluation of AII-antagonist losartan (HEAAL) study in patients intolerant to ACE-inhibitorEur J Heart Fail200810989990618768350
   PubMed Web of Science ®Google Scholar
• HunyadyLCattKJPleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin IIMol Endocrinol200620595397016141358
   PubMed Web of Science ®Google Scholar
• AndersenSSchalkwijkCGStehouwerCDParvingHHAngiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathyDiabetes Care20002371031103210895868
   PubMed Web of Science ®Google Scholar
• TsutamotoTWadaAMaedaKAngiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failureJ Am Coll Cardiol200035371472110716475
   PubMed Web of Science ®Google Scholar
• KhanBVNavalkarSKhanQARahmanSTParthasarathySIrbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery diseaseJ Am Coll Cardiol20013861662166711704378
   PubMed Web of Science ®Google Scholar
• NavalkarSParthasarathySSantanamNKhanBVIrbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosisJ Am Coll Cardiol200137244044411216960
   PubMed Web of Science ®Google Scholar
• PrasadAKohKKSchenkeWHRole of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosisAm Heart J2001142224825311479463
   PubMed Web of Science ®Google Scholar
• JilmaBLi-Saw-HeeFLWagnerOFBeeversDGLipGYEffects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1Clin Sci2002103213113612149103
   PubMed Web of Science ®Google Scholar
• RahmanSTLautenWBKhanQANavalkarSParthasarathySKhanBVEffects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation)Am J Cardiol200289668669011897210
   PubMed Web of Science ®Google Scholar
• RajagopalanSBrookRMehtaRHEffect of losartan in aging related endothelial impairmentAm J Cardiol200289556256611867042
   PubMed Web of Science ®Google Scholar
• WassmannSHilgersSLaufsUBohmMNickenigGAngiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunctionArterioscler Thromb Vasc Biol20022271208121212117739
   PubMed Web of Science ®Google Scholar
• AgarwalRProinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockadeAm J Physiol (Renal Physiol)20032844F863F86912505865
   PubMed Web of Science ®Google Scholar
• BaykalYYilmazMICelikTEffects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stressJ Hypertens20032161207121112777959
   PubMed Web of Science ®Google Scholar
• DandonaPKumarVAljadaAAngiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory actionJ Clin Endocrinol Metab20038894496450112970329
   PubMed Web of Science ®Google Scholar
• DohiYOhashiMSugiyamaMTakaseHSatoKUedaRCandesartan reduces oxidative stress and inflammation in patients with essential hypertensionHypertens Res200326969169714620923
   PubMed Web of Science ®Google Scholar
• KohKKAhnJYHanSHPleiotropic effects of angiotensin II receptor blocker in hypertensive patientsJ Am Coll Cardiol200342590591012957441
   PubMed Web of Science ®Google Scholar
• LautenWBKhanQARajagopalanSUsefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart diseaseAm J Cardiol20039191116111912714159
   PubMed Web of Science ®Google Scholar
• TakedaTHoshidaSNishinoMTanouchiJOtsuKHoriMRelationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levelsAtherosclerosis2003169115515812860262
   PubMed Web of Science ®Google Scholar
• FliserDBuchholzKHallerHfor the EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) InvestigatorsAntiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculation200411091103110715313950
   PubMed Web of Science ®Google Scholar
• GraningerMReiterRDruckerCMinarEJilmaBAngiotensin receptor blockade decreases markers of vascular inflammationJ Cardiovasc Pharmacol200444333533915475831
   PubMed Web of Science ®Google Scholar
• KohKKQuonMJHanSHAdditive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patientsCirculation2004110243687369215569835
   PubMed Web of Science ®Google Scholar
• SardoMACastaldoMCinquegraniMEffects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patientsAngiology200455219520315026875
   PubMed Web of Science ®Google Scholar
• SchiefferBBunteCWitteJComparative effects of AT1-antagonism and angiotensin converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery diseaseJ Am Coll Cardiol200444236236815261932
   PubMed Web of Science ®Google Scholar
• YasunariKMaedaKWatanabeTComparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophyJ Am Coll Cardiol200443112116212315172423
   PubMed Web of Science ®Google Scholar
• AnandISLatiniRFloreaVGfor the Val-HeFT InvestigatorsC-reactive protein in heart failure prognostic value and the effect of valsartanCirculation2005112101428143416129801
   PubMed Web of Science ®Google Scholar
• BiasucciLMLombardiMPiroMDi GiannuarioGLiuzzoGCreaFIrbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable anginaHeart200591567067115831660
   PubMed Web of Science ®Google Scholar
• ManabeSOkuraTWatanabeSFukuokaTHigakiJEffects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertensionJ Cardiovasc Pharmacol200546673573916306795
   PubMed Web of Science ®Google Scholar
• MiuraYYamamotoNTsunekawaSReplacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequencesDiabetes Care200528375775815735228
   PubMedGoogle Scholar
• RoseiEARizzoniDMuiesanMLfor the CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigatorsEffects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitusJ Hypertens200523243544415662233
   PubMed Web of Science ®Google Scholar
• RuilopeLMMalaccoEKhderYKandraABonnerGHeintzDEfficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST studyClin Ther200527557858715978306
   PubMed Web of Science ®Google Scholar
• KoulourisSSymeonidesPTriantafyllouKComparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitusAm J Cardiol200595111386138815904653
   PubMed Web of Science ®Google Scholar
• SchramMTvan IttersumFJSpoelstra-de ManAAggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trialJ Hum Hypertens200519642943715647778
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFD’AngeloATelmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alphaHypertens Res2006291184985617345784
   PubMed Web of Science ®Google Scholar
• LinkALenzMLegnerDBöhmMNickenigGTelmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytesJ Hypertens20062491891189816915040
   PubMed Web of Science ®Google Scholar
• NagelJMTietzABGokeBParhoferKGThe effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjectsMetabolism20065591149115416919531
   PubMed Web of Science ®Google Scholar
• NomuraSShouzuAOmotoSNishikawaMFukuharaSIwasakaTEffect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitusThromb Res2006117438539215896827
   PubMed Web of Science ®Google Scholar
• OgawaSMoriTNakoKKatoTTakeuchiKItoSAngiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathyHypertension200647469970516505207
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonERifaiNfor the Val-MARC InvestigatorsValsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trialHypertension2006481737916714425
   PubMed Web of Science ®Google Scholar
• HanSHKohKKQuonMJLeeYShinEKThe effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patientsAtherosclerosis2007190120521116500662
   PubMed Web of Science ®Google Scholar
• KohKKQuonMJLeeYAdditive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patientsEur Heart J200728121440144717483542
   PubMed Web of Science ®Google Scholar
• LiuLZhaoSPZhouHNLiQZLiJXEffect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertensionJ Cardiovasc Pharmacol2007501505517666915
   PubMed Web of Science ®Google Scholar
• RajagopalanSZannadFRadauceanuAEffects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertensionAm J Cardiol2007100222222617631074
   PubMed Web of Science ®Google Scholar
• YanoYHoshideSIshikawaJThe differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patientsAm J Hypertens200720556557217485023
   PubMed Web of Science ®Google Scholar
• WhiteMLepageSLavoieJEffects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failureJ Card Fail2007132869417395047
   PubMed Web of Science ®Google Scholar
• WillemsenJMWesterinkJWDallinga-ThieGMAngiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytesJ Cardiovasc Pharmacol200749161217261957
   PubMed Web of Science ®Google Scholar
• GalleJSchwedhelmEPinnettiSfor the VIVALDI investigatorsAntiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathyNephrol Dial Transplant200823103174318318450829
   PubMed Web of Science ®Google Scholar
• NakayamaSWatadaHMitaTComparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertensionHypertens Res200831171318360012
   PubMed Web of Science ®Google Scholar
• PackardRRLibbyPInflammation in atherosclerosis: from vascular biology to biomarker discovery and risk predictionClin Chem2008541243818160725
   PubMed Web of Science ®Google Scholar
• MarchesiCParadisPSchiffrinELRole of the renin-angiotensin system in vascular inflammationTrends Pharmacol Sci200829736737418579222
   PubMed Web of Science ®Google Scholar
• GriendlingKKUshio-FukaiMReactive oxygen species as mediators of angiotensin II signalingRegul Pept20009113212710967197
   PubMedGoogle Scholar
• BarnesPJKarinMNuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseasesN Engl J Med199733615106610719091804
   PubMed Web of Science ®Google Scholar
• FörstermannUOxidative stress in vascular disease: causes, defense mechanisms and potential therapiesNat Clin Pract Cardiovasc Med20085633834918461048
   PubMedGoogle Scholar
• OrtizMCManriquezMCRomeroJCJuncosLAAntioxidants block angiotensin II-induced increases in blood pressure and endothelinHypertension2001(3 pt2); 3865565911566950
   PubMed Web of Science ®Google Scholar
• GuzikTJHochNEBrownKARole of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunctionJ Exp Med2007204102449246017875676
   PubMed Web of Science ®Google Scholar
• BlackSKushnerISamolsDC-reactive proteinJ Biol Chem200427947484874849015337754
   PubMed Web of Science ®Google Scholar
• VermaSSzmitkoPERidkerPMC-reactive protein comes of ageNat Clin Pract Cardiovasc Med200521293616265340
   PubMedGoogle Scholar
• RoldánVMarínFLipGYBlannADSoluble E-selectin in cardiovascular disease and its risk factors. A review of the literatureThromb Haemost20039061007102014652631
   PubMed Web of Science ®Google Scholar
• RidkerPMHennekensCHRoitman-JohnsonBStampferMJAllenJPlasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy menLancet1998351909688929439492
   PubMed Web of Science ®Google Scholar
• HwangSJBallantyneCMSharrettARCirculating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) studyCirculation19979612421942259416885
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNStampferMJHennekensCHPlasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy menCirculation2000101151767177210769275
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNPfefferMSacksFLepageSBraunwaldEElevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarctionCirculation2000101182149215310801754
   PubMed Web of Science ®Google Scholar
• de LemosJAMorrowDABlazingMASerial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trialJ Am Coll Cardiol200750222117212418036447
   PubMed Web of Science ®Google Scholar
• ObisesanTOLeeuwenburghCPhillipsTC-reactive protein genotypes affect baseline, but not exercise training-induced changes, in C-reactive protein levelsArterioscler Thromb Vasc Biol200424101874187915271790
   PubMed Web of Science ®Google Scholar
• FoxERBenjaminEJSarpongDFEpidemiology, heritability, and genetic linkage of C-reactive protein in African Americans (from the Jackson Heart Study)Am J Cardiol2008102783584118805107
   PubMed Web of Science ®Google Scholar
• PrasadKC-reactive protein (CRP)-lowering agentsCardiovasc Drug Rev2006241335016939632
   PubMedGoogle Scholar
• NagatomoYYoshikawaTKohnoTEffects of beta-blocker therapy on high sensitivity C-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failureJ Card Fail200713536537117602983
   PubMed Web of Science ®Google Scholar
• JenkinsNPKeevilBGHutchinsonIVBrooksNHBeta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery diseaseAm J Med2002112426927411893365
   PubMed Web of Science ®Google Scholar
• GenserBGrammerTBStojakovicTSiekmeierRMaerzWEffect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysisInt J Clin Pharmacol Ther2008461049751018826864
   PubMed Web of Science ®Google Scholar
• GiuseppeRDi CastelnuovoACentrittoFRegular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy italian populationJ Nutr2008138101939194518806104
   PubMed Web of Science ®Google Scholar
• FelmedenDCSpencerCGChungNARelation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT])Am J Cardiol200392440040512914869
   PubMed Web of Science ®Google Scholar
• GISSI-HF investigatorsTavazziLMaggioniAPEffect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialLancet200837296451231123918757089
   PubMed Web of Science ®Google Scholar
• KasteleinJJAkdimFStroesESfor the ENHANCE InvestigatorsSimvastatin with or without ezetimibe in familial hypercholesterolemiaN Engl J Med2008358141431144318376000
   PubMed Web of Science ®Google Scholar
• RidkerPMFonsecaFAGenestJfor the JUPITER Trial Study GroupBaseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive proteinAm J Cardiol2007100111659166418036365
   PubMed Web of Science ®Google Scholar
• KinlaySLow-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysisJ Am Coll Cardiol200749202003200917512355
   PubMed Web of Science ®Google Scholar